Caris Life Sciences (CAI) on Thursday reported first-quarter results with revenue rising sharply from last year while losses narrowed, driven by strong growth in molecular profiling services.
Total revenue increased to $216.2 million in the first quarter of 2026 from $120.9 million in the same period last year.
The company posted an operating income of $5.3 million, compared with an operating loss of $58.0 million a year earlier. Net loss narrowed to $0.5 million, or $0.00 per share, from $102.6 million, or $3.57 per share, in the first quarter of 2025.
CAI is currently trading after hours at $16.94, down $2.90 or 14.62 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.